Progress on chemotherapy for peritoneal carcinomatosis
10.3969/j.issn.1000-8179.2020.03.632
- VernacularTitle: 腹膜转移癌内科治疗新进展
- Author:
Yingying HUANG
1
Author Information
1. Department of Oncology, Beijing Hospital, National Center of Gerontology
- Publication Type:Journal Article
- Keywords:
Cytoreductive surgery (CRS);
Hyperthermia intraperitoneal chemotherapy (HIPEC);
Intraperitoneal chemotherapy;
Peritoneal carcinomatosis;
Pressurized intraperitoneal aerosol chemotherapy
- From:
Chinese Journal of Clinical Oncology
2020;47(3):123-127
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal carcinomatosis is obtaining extensive attention because of its late detection and poor prognosis. Lately, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are widely used for the treatment of this condition and could be effective in some carefully selected patients. Different chemotherapies are combined with CRS or HIPEC, and different drug administration routes are used, such as intraperitoneal or pressurized intraperitoneal aerosol chemotherapy. Furthermore, the results of many clinical trials differed among patients with different types of cancer. Herein, we reviewed recent studies in patients with gastric, colon, and ovarian cancer to evaluate the progress of chemotherapy for peritoneal carcinomatosis.
